News|Videos|December 8, 2025

Beyond Weight Loss: How GLP-1 RAs Established a Role in Cardiology in 2025

Name: Beyond Weight Loss: How GLP-1 RAs Established a Role in Cardiology in 2025
Uploaded: 2025-12-09T00:00:07.267Z
Duration: 8 min 37 s
Description: Beyond Weight Loss: How GLP-1 RAs Established a Role in Cardiology in 2025

Author(s)Viet Le, DMSc, PA-C, Stephen Greene, MD, Justin Ezekowitz, MD

Fact checked by: Ryan Livingston, Patrick Campbell

GLP-1 receptor agonists revolutionize treatment in cardiology, offering new hope for heart failure and related conditions beyond weight loss.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are one of the fastest-growing drug families in medicine today. From humble beginnings as a method of insulin and glucagon management in patients with type 2 diabetes (T2D), GLP-1s have expanded into hepatology, cardiology, and even ophthalmology. Their role as an anti-inflammatory agent, coupled with their weight loss capabilities, has rocketed GLP-1 RAs to one of the top drugs in the industry.